The BRAF V600E melanoma cell line was used as the parental cell line, and several clinically relevant point mutations associated with acquired BRAF inhibitor resistance were introduced into genes that act either upstream or downstream of BRAF in the Ras/Raf/MEK/ERK kinase signaling pathway ([112]; www.atcc.org). This evidence concerns the gene BRAF and melanoma.